[Legal Talk] "Korean Biopharma Licensing" (partnering with Korean Pharmaceutical and Biopharma Manufacturers Association)

-

 



Introducing my latest video partnering with the ‘Korean Pharmaceutical and Bio-pharma Manufacturers Association’ on 'Useful licensing tips for Biopharma companies'.

Youtube video link: https://youtu.be/SuscTNYxBRI?si=7NCsJG38FC05DPLm


Location: Seoul, South Korea

Comments

Post a Comment

Popular posts from this blog

Introduction of Dr. Woojin Lee, J.D., Ph.D.

-
Image
Before starting her career as a lawyer providing legal services for Life Science and Pharmaceutical companies, Woojin earned a Ph.D. degree in Neuroscience at the University College London, Institute of Neurology, as a government scholarship recipient and a Master's degree in Oncology at the University of Nottingham,   at the School of Molecular Medical Science  in the U.K.  Woojin is a skilled advisory lawyer sought by many Life Science and Pharmaceutical companies in South Korea, based on her in-depth experience from Life Science research in the laboratory, global clinical trials and working as an IP lawyer before opening her own specialized practice in year 2020.   Woojin also has experience as a professional academic consultant in the field of English Medical Writing and has been recognized for her expertise in lectures for Medical Science Communication. ▲ J.D. at Ewha Law School, Attorney at Law, Patent Attorney (2016) ▲ Ph.D. Neuroscience...
Read more

New roles for South Korea's 'Convergence AI Institute for Drug Discovery'

-
Image
Earlier this year, The 'Korea Pharmaceutical and Bio-Pharma Manufacturers Association(KPBMA)' officially launched the 'Convergence AI Institute for Drug Discovery(CAIID)' and held the grand opening ceremony on January 31st. The South Korean CAIID aims to serve as a hub for jointly planning and executing digital convergence research and aims to establish safe utilization platform for diverse data, which may enhance the performance of AI.  The CAIID's head Hwajong Kim stated, "Currently, pharmaceutical companies are collaborating individually with AI companies. However, there is no perfect match between the data held by pharmaceutical companies and the advantages of each solution provider." He continued, "Since each pharmaceutical company possesses different data, the approach to AI should also vary. However, at this point, we cannot predict this in advance, which limits us." He emphasized, "It is not a stage to debate whether this business wi...
Read more